No Data
No Data
FOSUN PHARMA (02196): HENLIUS (02696) will retain its Listed in Hong Kong status and continue to support its long-term healthy development.
On January 22, 2025, FOSUN PHARMA (600196.SH; 02196) did not reach a special resolution regarding the absorption and merger with the privatization of HENLIUS (02696), and the absorption and merger will not be implemented, allowing HENLIUS to retain its Listed in Hong Kong status.
Express News | RPT-Shanghai Fosun Pharma - Merger Was Not Approved at H Shareholders' Class Meeting.
Express News | Corrected-Shanghai Fosun Pharma - Proposed Privatisation of Shanghai Henlius Biotech (Not Co) Will Not Proceed and Listing of H Shares on Main Board of Stock Exchange Will Be Maintained
Fosun Pharma's Privatization Proposal for Henlius Falls Through
Express News | Shanghai Fosun Pharmaceutical Says It Plans to Buy Back 300-600 Mln Yuan of Company a-Shares Between Jan 22 and July 21
Express News | Shanghai Fosun Pharma - Proposed Privatisation of Company Will Not Proceed and Listing of H Shares on Main Board of Stock Exchange Will Be Maintained